QBiotics Poster Presentation at SITC 2022
22 December 2022
Presentation of new pre-clinical data from an ongoing research collaboration with the QIMR Berghofer Medical Research Institute at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022) held in Boston, USA in November 2022.
A Poster presentation shows that QBiotics lead oncology molecule tigilanol tiglate directly destroys injected tumours, as well as induces systemic immunity and has the potential to induce responses in non-injected tumours.
Data shows that tigilanol tiglate induces immunogenic cell death via oncosis and induces tumour-specific T cells and protects against distal tumour growth in mouse models of cancer. Tigilanol tiglate also enhances anti-tumour responses and survival in mice treated with immune check point inhibitors.
Tigilanol tiglate is currently being tested in Phase I/II clinical trials in patients with head and neck cancers (ACTRN12619001407189), soft tissue sarcomas, and Stage IIIB to IVM1c melanoma as either a monotherapy (NCT05234437) or in combination with pembrolizumab (KEYTRUDA®, Merck & Co.) (NCT04834973).